The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Nadroparin calcium Aspen Forte 19,000 I.U. anti-Xa/ml solution for injection in a pre-filled syringe



Mylan IRE Healthcare LimitedPA2010/065/003

Main Information

Trade NameNadroparin calcium Aspen Forte 19,000 I.U. anti-Xa/ml solution for injection in a pre-filled syringe
Active SubstancesNadroparin calcium
Dosage FormSolution for injection in pre-filled syringe
Licence HolderMylan IRE Healthcare Limited
Licence NumberPA2010/065/003

Group Information

ATC CodeB01AB Heparin group
B01AB06 nadroparin

Status

License statusWithdrawn
Withdrawn Date29/07/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back